| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World |
|
American Journal of Hematology |
Aplastic Anemia |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
|
Blood |
Aplastic Anemia |
| Eltrombopag in children with severe aplastic anemia |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
